Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

ALZHEIMER DISEASE

Disease modification is not all — we need symptomatic therapies for Alzheimer disease

Nature Reviews Neurology volume 18, pages 3–4 (2022)Cite this article

Subjects

A new study found methylphenidate to be effective in treating apathy in individuals with Alzheimer disease. At a time when the recent aducanumab approval is focusing attention on the promise of disease-modifying therapies, the new findings highlight the importance of developing better symptomatic treatment options for individuals with psychiatric disorders of Alzheimer disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Vigen, C. L. et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD. Am. J. Psychiatry 168, 831–839 (2011).

    Article  Google Scholar 

  2. Cummings, J., Lee, G., Zhong, K., Fonseca, J. & Taghva, K. Alzheimer’s disease drug development pipeline: 2021. Alzheimers Dement. (N.Y.) 7, e12179 (2021).

    Google Scholar 

  3. Mintzer, J. et al. Effect of methylphenidate on apathy in patients with Alzheimer disease: the ADMET 2 randomized clinical trial. JAMA Neurol https://doi.org/10.1001/jamaneurol.2021.3356 (2021).

    Article  PubMed  Google Scholar 

  4. Marshall, G. A., Fairbanks, L. A., Tekin, S., Vinters, H. V. & Cummings, J. L. Neuropathologic correlates of apathy in Alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 21, 144–147 (2006).

    Article  Google Scholar 

  5. Miller, D. S. et al. Diagnostic criteria for apathy in neurocognitive disorders. Alzheimers Dement. (2021).

  6. Rosenberg, P. B. et al. Safety and efficacy of methylphenidate for apathy in Alzheimer’s disease: a randomized, placebo-controlled trial. J. Clin. Psychiatry 74, 810–816 (2013).

    Article  CAS  Google Scholar 

  7. Rabinovici, G. D. Controversy and progress in Alzheimer’s disease — FDA approval of aducanumab. N. Engl. J. Med. 385, 771–774 (2021).

    Article  CAS  Google Scholar 

  8. Naglie, G. et al. Predictors of family caregiver ratings of patient quality of life in Alzheimer disease: cross-sectional results from the Canadian Alzheimer’s Disease Quality of Life Study. Am. J. Geriatr. Psychiatry 19, 891–901 (2011).

    Article  Google Scholar 

  9. Tariot, P. N. et al. Trial of pimavanserin in dementia-related psychosis. N. Engl. J. Med. 385, 309–319 (2021).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA

    Jeffrey Cummings

Authors
  1. Jeffrey Cummings
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey Cummings.

Ethics declarations

Competing interests

J.C. has provided consultation to Acadia, Alkahest, Behren Therapeutics, Biogen, Cassava, Cortexyme, EIP Pharma, Eisai, GemVax, Genentech, Green Valley, Grifols, Janssen, Karuna, LSP, Merck, Novo Nordisk, Otsuka, ReMYND, Resverlogix, Roche, Signant Health, Vaxxinity, and Unlearn AI pharmaceutical and assessment companies. J.C. owns the copyright of the Neuropsychiatric Inventory. J.C. has the following research support: NIGMS P20GM109025; NINDS U01NS093334; NIA R01AG053798; NIA P20AG068053; and NIA R35AG71476.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cummings, J. Disease modification is not all — we need symptomatic therapies for Alzheimer disease. Nat Rev Neurol 18, 3–4 (2022). https://doi.org/10.1038/s41582-021-00591-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-021-00591-9

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing